8-K: XOMA Royalty to Acquire LAVA Therapeutics for Cash, CVR

XOMA Royalty Corporation will acquire LAVA Therapeutics N.V. for a cash payment per share plus a contingent value right, following a unanimous board recommendation.

Summary

• XOMA Royalty Corporation will acquire LAVA Therapeutics N.V. through a tender offer for a price per share of $1.16 to $1.24 in cash, plus one non-transferable contingent value right (CVR) per share.
• The CVR represents the right to receive potential cash payments, including 100% of excess Closing Net Cash, 100% of net proceeds from LAVA-1266 disposition prior to closing, 75% of net proceeds from post-closing dispositions of CVR Products, and 75% of net proceeds from existing collaborations with Pfizer and Johnson & Johnson, all for a period of 10 years.
• LAVA's Board of Directors unanimously determined the acquisition is in the best interests of the company and its stakeholders, recommending shareholders accept the offer and vote in favor of related resolutions.
• The tender offer is expected to commence by August 15, 2025, and is subject to customary conditions, including a minimum tender of 80% (or 75% in certain cases) of LAVA's outstanding shares and a minimum cash balance of $31,500,000 at closing.
• Following the tender offer, LAVA will undergo a corporate reorganization (Dutch statutory merger) to become a private entity, with remaining minority shareholders receiving the same cash and CVR consideration.
• LAVA announced the discontinuation of its Phase 1 clinical trial for LAVA-1266 in acute myeloid leukemia and myelodysplastic syndrome, initiating a wind-down of the program.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the discontinuation of a clinical trial is a negative, the acquisition provides a clear cash value and a CVR, offering shareholders a structured exit with potential upside from partnered assets, which is a reasonable outcome given the circumstances.

Positives

• LAVA's Board of Directors unanimously recommended the acquisition, indicating it is in the best interests of the company and its stakeholders.
• The transaction includes a Contingent Value Right (CVR) which provides LAVA shareholders with potential future cash payments tied to the success of partnered assets (Pfizer and Johnson & Johnson collaborations) and any future out-licensing or sale of unpartnered programs, offering upside potential beyond the initial cash consideration.
• The acquisition provides a clear exit strategy and liquidity for LAVA shareholders, especially given the discontinuation of a key clinical trial (LAVA-1266).

Negatives

• LAVA announced the discontinuation of its Phase 1 clinical trial for LAVA-1266, a key program for acute myeloid leukemia and myelodysplastic syndrome, and will wind down the program.
• The CVRs are non-transferable, limiting liquidity for shareholders who wish to monetize their contingent rights immediately.
• The CVRs are highly speculative, with no assurance that holders will receive any payments, and do not represent any equity or ownership interest in the acquiring entity.

Risks

• Various closing conditions set forth in the Purchase Agreement may not be satisfied or waived, including uncertainties regarding the percentage of LAVA shareholders tendering their shares in the Offer.
• Competing offers may be made, potentially disrupting the current transaction.
• The transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and share price.
• Shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Activities related to the CVR Agreement may not result in any value to LAVA's shareholders.
• Prior to the completion of the transactions, LAVA's or XOMA's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Purchase Agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities.

Future Outlook

The transaction is expected to close in the fourth quarter of 2025, subject to the satisfaction of various closing conditions, including shareholder approval and a minimum tender of shares. The CVRs offer potential future payments to shareholders based on the success of LAVA's partnered assets and any future out-licensing or sale of unpartnered programs over the next 10 years, though there is no assurance of any payments from the CVRs.

Management Comments

• Owen Hughes, CEO of XOMA Royalty: 'We are adding economics related to LAVAs partnered programs investigating the utility of gamma delta bispecific antibodies, which hold significant promise for patients.'
• Steve Hurly, CEO of LAVA: 'The Purchase Agreement with XOMA Royalty announced today is the result of a thorough and wide-ranging strategic review process, conducted with the support of our legal and financial advisors, aimed at maximizing shareholder value while participating in the sustained success of LAVAs business.'

Industry Context

This acquisition highlights a trend in the biotechnology sector where royalty aggregators like XOMA Royalty seek to acquire future economics from therapeutic candidates, providing non-dilutive funding to biotech companies. For LAVA Therapeutics, a clinical-stage biopharmaceutical company, this transaction provides an exit and liquidity, especially significant given the discontinuation of a Phase 1 clinical trial for LAVA-1266. The inclusion of a CVR reflects a common mechanism in biotech M&A to bridge valuation gaps and allow selling shareholders to participate in the future success of specific assets, particularly those in early or mid-stage development or under existing partnerships.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Risk of shareholder or other litigation in connection with the transactions, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Certain of LAVA's directors and executive officers entered into tender and support agreements with XOMA Royalty, agreeing to tender their shares (approximately 0.5% of outstanding shares) into the offer. This is a disclosed related party transaction.

Stakeholder Impact

• Shareholders: Will receive cash and CVRs, providing liquidity and potential future upside, but the company will be delisted and cease public trading.
• Employees: Board considered their interests in approving the transaction. Employment contracts are expected to remain in force with the successor entity (New Topco).
• Partners (Pfizer, Johnson & Johnson): Collaborations are expected to continue, with CVR payments tied to their success, indicating continued value generation from these partnerships.
• Customers, Suppliers, Vendors: There is a risk of significant disruptions to business relationships due to transaction-related uncertainty.

Next Steps

• XOMA Royalty to commence a tender offer by August 15, 2025.
• LAVA to hold an extraordinary general meeting (EGM) for shareholder approval of resolutions related to the transaction and post-offer reorganization.
• Following the tender offer and a subsequent offering period, a corporate reorganization (Dutch statutory merger) will be effected, leading to LAVA becoming a private company.
• LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 and initiate the wind-down of the program.

Key Dates

Recommendation

For existing LAVA Therapeutics shareholders, a 'Hold' recommendation is appropriate. The acquisition offers a defined cash value per share, providing immediate liquidity. The inclusion of a Contingent Value Right (CVR) offers potential additional upside from LAVA's partnered assets and any future out-licensing of unpartnered programs. While the LAVA-1266 trial discontinuation is a negative, the overall transaction provides a structured exit with potential future value, making it reasonable to hold shares until the tender offer closes to receive the full consideration, including the CVR.

Keywords

Acquisition, Tender Offer, Contingent Value Right, CVR, Biotechnology, Pharmaceutical, Oncology, Gamma Delta T Cell Engagers, EGFRd2, JNJ-89853413, LAVA-1266, XOMA Royalty, LAVA Therapeutics, Merger, Delisting, SEC Filing